Patents by Inventor Trevor Stitt

Trevor Stitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250017183
    Abstract: Non-human animal cells and non-human animals comprising a humanized Cacng1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Cacng1 locus express a human CACNG1 protein or fragments thereof.
    Type: Application
    Filed: November 4, 2022
    Publication date: January 16, 2025
    Inventors: Trevor Stitt, Susannah Brydges, Alexander O. Mujica, Roxanne Ally
  • Publication number: 20240182561
    Abstract: The present disclosure provides Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 1 (CACNG1) antigen-binding proteins and protein-drug conjugates including a CACNG1 antigen-binding protein conjugated to a molecular cargo (e.g., a polynucleotide molecule, a polypeptide molecule, a carrier, or a small molecule) for delivery of the molecular cargo to skeletal muscle tissue and/or cells. Methods for treating, preventing, or reducing the likelihood of various skeletal muscle diseases and/or disorders with such antigen-binding proteins or protein-drug conjugates are also provided.
    Type: Application
    Filed: November 3, 2023
    Publication date: June 6, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor STITT, Michael Stec, Sandra Kleiner, Andrew J. Murphy, Amy Han
  • Publication number: 20240117027
    Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.
    Type: Application
    Filed: April 17, 2023
    Publication date: April 11, 2024
    Inventors: Trevor Stitt, Esther Latres
  • Publication number: 20240067712
    Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.
    Type: Application
    Filed: October 11, 2022
    Publication date: February 29, 2024
    Inventors: Trevor Stitt, Esther Latres
  • Patent number: 11655291
    Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: May 23, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres
  • Publication number: 20200010540
    Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.
    Type: Application
    Filed: July 17, 2019
    Publication date: January 9, 2020
    Inventors: Trevor Stitt, Esther Latres
  • Patent number: 10400036
    Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: September 3, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres
  • Publication number: 20190023777
    Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.
    Type: Application
    Filed: January 2, 2018
    Publication date: January 24, 2019
    Inventors: Trevor Stitt, Esther Latres
  • Publication number: 20180171006
    Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.
    Type: Application
    Filed: February 9, 2018
    Publication date: June 21, 2018
    Inventors: Trevor Stitt, Esther Latres
  • Patent number: 9890212
    Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 13, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres
  • Publication number: 20170226197
    Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.
    Type: Application
    Filed: September 30, 2016
    Publication date: August 10, 2017
    Inventors: Trevor Stitt, Esther Latres
  • Publication number: 20170008956
    Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.
    Type: Application
    Filed: March 22, 2016
    Publication date: January 12, 2017
    Inventors: Trevor Stitt, Esther Latres
  • Publication number: 20160340421
    Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.
    Type: Application
    Filed: December 18, 2015
    Publication date: November 24, 2016
    Inventors: Trevor Stitt, Esther Latres
  • Patent number: 9260515
    Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: February 16, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres
  • Publication number: 20150010568
    Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.
    Type: Application
    Filed: September 25, 2014
    Publication date: January 8, 2015
    Inventors: Trevor Stitt, Esther Latres
  • Publication number: 20140356369
    Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Inventors: Trevor Stitt, Esther Latres
  • Patent number: 8871209
    Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: October 28, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres
  • Patent number: 8840894
    Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: September 23, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres
  • Publication number: 20110293630
    Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.
    Type: Application
    Filed: May 25, 2011
    Publication date: December 1, 2011
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres
  • Patent number: 7632503
    Abstract: A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.
    Type: Grant
    Filed: February 14, 2008
    Date of Patent: December 15, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres, David J. Glass